RxDoctor Payments Data

Nureain Mirza, MD

Critical Care Medicine · Oak Lawn, ILNPI 1205876414

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (47.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Intuitive Surgical at 50.7% of the total. 2025 is the largest year on record at $13,241, more than ten times the $407 reported in 2019. Among critical care medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,670in general payments, 2019–2025

Across 194 payments — averaging $111.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$11K
  • AstraZeneca$6K
  • GSK$901
  • Boehringer Ingelheim$658
  • Jazz Pharmaceuticals Inc.$558
  • Inspire Medical Systems, Inc.$294
  • plus $2K from 26 others

What the payments were for

  • Speaking & faculty fees$5,60026%
  • Travel & lodging$8304%
  • Food & beverage$5,04023%
  • Education$10,20047%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,670 in reported general payments places this provider in the 95th percentile of 281 critical care medicine providers in Illinois.

See all critical care medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$389,515
Medicare patients
603
Services billed
3,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate25$323,191
Trelegy ElliptaFluticasone/Umeclidin/Vilanter195$225,524
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr81$61,914
Breztri AerosphereBudesonide/Glycopyr/Formoterol46$40,103
Breo ElliptaFluticasone/Vilanterol60$38,136
Incruse ElliptaUmeclidinium Bromide28$20,397
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$12,312
Spiriva RespimatTiotropium Bromide12$8,717
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$6,631
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$6,443
Wixela InhubFluticasone Propion/Salmeterol23$4,723
SymbicortBudesonide/Formoterol Fumarate14$3,825
Albuterol Sulfate HfaAlbuterol Sulfate126$3,775
Arnuity ElliptaFluticasone Furoate14$3,666
Ventolin HfaAlbuterol Sulfate35$2,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$901$349,637378 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$658$344,22054 claims
AstraZenecaBreztri Aerosphere, Symbicort$6,252$43,92860 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 critical care medicine providers in Illinois.

Other critical care medicine in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →